Lenograstim

Generic Name: Lenograstim

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 135968-09-1

Unique Ingredient Identifier: 6WS4C399GB

Background: Lenograstim is a recombinant granulocyte colony-stimulating factor used as an immunostimulating agent.

Indication: The drug is used to reduce the risk of life-threatening infection in patients with neutropenia, particularly after cytotoxic chemotherapy.
...

Associated Conditions: Neutropenia

Associated Therapies: Mobilization of hematopoietic stem cells

Clinical Trials

Donation of Whole Blood by Healthy Volunteers After Mobilisation by Haematopoietic Growth Factor (Rhu-G-CSF = Granocyte)

Phase 1

Recruiting

Conditions: Healthy Volunteers

Interventions: Drug: Lenograstim

First Posted Date: 2022-10-26

Last Posted Date: 2024-07-10

Lead Sponsor: CellProthera

Target Recruit Count: 40

Registration Number: NCT05594433

Locations: 🇫🇷
GHU La Pitié-Salpêtrière, Paris, France
🇫🇷
CHRU Strasbourg, Strasbourg, France

Efficacy of Granulocyte-Colony Stimulating Factor (G-CSF)

Not Applicable

Conditions: Neutropenia

Interventions: Drug: lenograstim

First Posted Date: 2018-04-13

Last Posted Date: 2018-04-13

Lead Sponsor: DERSHENG SUN

Target Recruit Count: 155

Registration Number: NCT03498248

Locations: 🇰🇷
the Catholic university of Korea, Seoul, Gyounggido, Korea, Republic of

Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 3

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Fludarabine
Drug: Azacitadine
Drug: Cytarabine
Drug: Lenograstim
Drug: Filgastrim

First Posted Date: 2014-12-18

Last Posted Date: 2020-04-06

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 289

Registration Number: NCT02319135

Locations: 🇪🇸
Hospital Universitari i Politècnic La Fe, Valencia, Spain

A Phase II Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles In Patients With Castration-Resistant Prostate Cancer (MEL-CAP)

Phase 2

Terminated

Conditions: Castrate Resistant Prostate Cancer

Interventions: Drug: Melphalan
Drug: Lenograstim

First Posted Date: 2013-07-24

Last Posted Date: 2023-04-19

Lead Sponsor: Barts & The London NHS Trust

Target Recruit Count: 29

Registration Number: NCT01907009

Locations: 🇬🇧
St Batholowmew's Hospital NHS, London, United Kingdom

Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine

Phase 2

Completed

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: Cytarabine
Drug: Idarubicin
Drug: Etoposide
Drug: Lenograstim
Drug: Azacitidine

First Posted Date: 2010-08-12

Last Posted Date: 2020-12-31

Lead Sponsor: University of Ulm

Target Recruit Count: 277

Registration Number: NCT01180322

Locations: 🇦🇹
Universitätsklinikum Innsbruck, Innsbruck, Austria
🇩🇪
Universitätsklinikum Schleswig-Holstein, Kiel, Germany
🇦🇹
Krankenhaus der Barmherzigen Schwestern, Linz, Austria

and more 40 locations

Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose Therapy

Phase 2

Completed

Conditions: Hodgkin's Disease
Non-Hodgkin Lymphomas
Multiple Myelomas

Interventions: Drug: lenograstim

First Posted Date: 2010-03-11

Last Posted Date: 2010-03-11

Lead Sponsor: WiSP Wissenschaftlicher Service Pharma GmbH

Target Recruit Count: 169

Registration Number: NCT01085058

Study on the Incidence of Febrile Episodes During Stem Cells Collection After Chemotherapy in Patients With Multiple Myeloma

Phase 3

Conditions: G-CSF, Multiple Myeloma, Febrile Episode, Filgrastim, Leograstim

Interventions: Drug: filgrastim
Drug: lenograstim

First Posted Date: 2009-07-03

Last Posted Date: 2009-07-03

Lead Sponsor: University of Pisa

Target Recruit Count: 180

Registration Number: NCT00932217

Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma

Phase 3

Conditions: Diffuse Large B-Cell Lymphoma
IPI≥2

Interventions: Drug: Rituximab
Drug: Vincristina
Drug: Ciclofosfamide
Drug: Prednisone
Drug: Doxorubicina
Drug: Pegfilgrastim
Drug: Mitoxantrone
Drug: ARA-C
Drug: Lenograstim
Drug: BCNU
Drug: VP-16
Procedure: ASCT

First Posted Date: 2007-07-11

Last Posted Date: 2011-02-15

Lead Sponsor: Fondazione Italiana Linfomi - ETS

Target Recruit Count: 399

Registration Number: NCT00499018

Locations: 🇮🇹
Istituto Vito Fazzi, Lecce, Italy
🇮🇹
Ospedale Umberto I - DH Oncoematologico, Nocera Inferiore, Salerno, Italy
🇮🇹
Az. Osp. SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy

and more 71 locations

Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL

Phase 1

Completed

Conditions: Lymphoma, Large-Cell, Diffuse
Lymphoma, B-Cell

Interventions: Drug: Bortezomib
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisolone
Drug: Lenograstim

First Posted Date: 2006-09-22

Last Posted Date: 2013-03-15

Lead Sponsor: Asan Medical Center

Target Recruit Count: 49

Registration Number: NCT00379574

Locations: 🇰🇷
Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of
🇰🇷
Asan Medical Cener, Seoul, Korea, Republic of

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy